Effect of Chemokine (C-C Motif) Ligand 7 (CCL7) and Its Receptor (CCR2) Expression on Colorectal Cancer Behaviors

Colorectal cancer is the source of one of the most common cancer-related deaths worldwide, where the main cause of patient mortality remains metastasis. The aim of this study was to determine the role of CCL7 (chemokine (C-C motif) ligand 7) in tumor progression and finding whether it could predict survival of colorectal cancer patients. Initially, our study focused on the crosstalk between mesenchymal stem cells (MSCs) and CT26 colon carcinoma cells and resulted in identifying CCL7 as a chemokine upregulated in CT26 colon cancer cells cocultured with MSCs, compared with CT26 in monoculture in vitro. Moreover, we showed that MSCs enhance CT26 tumor cell proliferation and migration. We analyzed the effect of CCL7 overexpression on tumor progression in a murine CT26 model, where cells overexpressing CCL7 accelerated the early phase of tumor growth and caused higher lung metastasis rates compared with control mice. Microarray analysis revealed that tumors overexpressing CCL7 had lower expression of immunoglobulins produced by B lymphocytes. Additionally, using Jh mutant mice, we confirmed that in the CT26 model, CCL7 has an immunoglobulin-, and thereby, B-cell-dependent effect on metastasis formation. Finally, higher expression of CCL7 receptor CCR2 (C-C chemokine receptor type 2) was associated with shorter overall survival of colorectal cancer patients. Altogether, we showed that CCL7 is essentially involved in the progression of colorectal cancer in a CT26 mouse model and that the expression of its receptor CCR2 could be related to a different outcome pattern of patients with colorectal carcinoma.

Download Full-text

Role of Enhanced Recovery Program for Colorectal Cancer Patients: National Cancer Institute Experience

Indian Journal of Surgical Oncology ◽

10.1007/s13193-021-01278-9 ◽

2021 ◽

Author(s):

Mamdouh Mohamed Mounir ◽

Mohamed Ibrahim Fahim

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

National Cancer Institute ◽

Enhanced Recovery ◽

Enhanced Recovery Program ◽

Colorectal Cancer Patients ◽

Recovery Program

Download Full-text

The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild type colorectal cancer patients receiving irinotecan/cetuximab

Annals of Oncology ◽

10.1093/annonc/mdx422.021 ◽

2017 ◽

Vol 28 ◽

pp. vi9-vi10

Author(s):

M. Puzzoni ◽

L. Demurtas ◽

R. Giampieri ◽

P. Ziranu ◽

V. Pusceddu ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Copy Number ◽

Primary Tumour ◽

Gene Copy Number ◽

Gene Copy ◽

Wild Type ◽

Egfr Gene ◽

Colorectal Cancer Patients

Download Full-text

The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapy

Tumor Biology ◽

10.1007/s13277-014-2693-3 ◽

2014 ◽

Vol 36 (3) ◽

pp. 1519-1527 ◽

Cited By ~ 12

Author(s):

M. Tampellini ◽

A. Ottone ◽

I. Alabiso ◽

C. Baratelli ◽

L. Forti ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Advanced Colorectal Cancer ◽

Time Dependent ◽

Prognostic Role ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Colorectal Cancer Patients

Download Full-text

Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients

Expert Opinion on Drug Metabolism & Toxicology ◽

10.1080/17425255.2021.1974397 ◽

2021 ◽

pp. 1-7

Author(s):

Pau Riera ◽

David Páez

Keyword(s):

Colorectal Cancer ◽

Adverse Events ◽

Metastatic Colorectal Cancer ◽

Cancer Patients ◽

Colorectal Cancer Patients

Download Full-text

High Expression of sLex Associated with Poor Survival in Argentinian Colorectal Cancer Patients

The International Journal of Biological Markers ◽

10.5301/jbm.5000060 ◽

2014 ◽

Vol 29 (1) ◽

pp. e30-e39 ◽

Cited By ~ 5

Author(s):

Ariel Zwenger ◽

Martin Rabassa ◽

Sandra Demichelis ◽

Gabriel Grossman ◽

Amada Segal-Eiras ◽

...

Keyword(s):

Colorectal Cancer ◽

Lymph Nodes ◽

Cancer Patients ◽

Normal Mucosa ◽

Poor Survival ◽

Primary Tumors ◽

Metastatic Lymph Nodes ◽

Metastatic Lymph ◽

Colorectal Cancer Patients

Aim Colorectal cancer (CRC) is one of the most prevalent malignancies in Argentina with 11,043 new cases and 6,596 deaths estimated to have occurred in 2008. The present study was developed to clarify the differential expression of MUC1, MUC2, sLex, and sLea in colorectal cancer patients and their relationship with survival and clinical and histological features. Methods Ninety primary tumor samples and 43 metastatic lymph nodes from CRC patients were studied; follow-up was documented. Twenty-six adenoma and 68 histological normal mucosa specimens were analyzed. An immunohistochemical approach was applied and statistical analysis was performed. Results In tumor samples, MUC1, sLea, and sLex were highly expressed (94%, 67%, and 91%, respectively); also, we found a significantly increased expression of the 3 antigens in primary tumors and metastatic lymph nodes compared with normal mucosa and adenomas. MUC2 was expressed in 52% of both normal mucosa and CRC samples; this reactivity significantly decreased in metastatic lymph nodes (p<0.05). A multiple comparison analysis showed that MUC1 and sLex discriminated among 3 groups: normal, adenoma, and CRC tissues. The increase of sLex expression showed an association with recurrence, and survival analysis showed that a high sLex staining was significantly associated with a poor survival. By multivariate analysis MUC1 inmunoreactivity correlated positively and significantly with tumor size, while MUC2 expression showed the opposite correlation. Conclusions The correlation of sLex overexpression in primary tumors and metastatic lymph nodes, the discrimination among the normal, adenoma, and CRC groups based on sLex expression, as well as its association with recurrence and survival, all suggest a prognostic role of sLex in Argentinian CRC patients.

Download Full-text